← Back to Search

Anti-alcoholism Medication

Disulfiram for Retinal Degeneration

Phase 1
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 180
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if a drug called disulfiram, commonly known as Antabuse, can improve vision in patients with retinal degeneration who also have an alcohol use disorder. The drug

Who is the study for?
This trial is for patients with various types of retinal degeneration, such as Stargardt Disease and Age-Related Macular Degeneration. Participants must also be receiving disulfiram for alcohol use disorder management. Specific inclusion and exclusion criteria details are not provided.
What is being tested?
The study is testing the effects of oral disulfiram (Antabuse®) on improving vision in patients with retinal degeneration. It's based on findings that it may reduce hyperactivity in the retina by decreasing Retinoic Acid synthesis.
What are the potential side effects?
While specific side effects related to this trial aren't listed, common side effects of disulfiram can include drowsiness, headache, metallic taste, skin rash, and in some cases more severe reactions like liver problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 180 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS
Secondary study objectives
mean change in National Eye Institute-Visual Functioning Questionnaire 25 composite score.
mean change in cone and rod amplitude assessed using Full field electroretinogram (ffERG)
mean change in cone and rod amplitude assessed using multifocal electroretinogram (mfERG)
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention
Participants will receive either drug or placebo for 180 days.

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
866 Previous Clinical Trials
545,370 Total Patients Enrolled
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top